|Articles|December 16, 2005
TOPRA confirms appointment of European Commission official to Advisory Council
Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.
Advertisement
TOPRA received yet another endorsement of its leading role in the global regulatory affairs industry. Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.
Mr. Behrndt has enjoyed an illustrious career at the European Commission, previously serving as the Acting Head of the Directorate F2. Mr. Behrndt has served the Commission since 2000 as a lawyer and advisor. Previously, he served as a lawyer and researcher for a variety of organisations and entities within Germany. He holds law degrees from Germany and the United Kingdom as well as having a Ph.D. in public administration and law.
TOPRA's President, Margareth Jorvid said, "We are delighted that Nils has joined our ranks. TOPRA will benefit immensely from his guidance and technical expertise offered through our Advisory Council."
Ms. Jorvid went onto say, "I think that this appointment really shows the maturity of our organisation and our expanding appeal worldwide, but most especially within the European Union. We are proud to have such a high-ranking official from the European Commission join TOPRA's Advisory Council."
TOPRA members are currently drawn from 52 countries.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
2
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
3
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
4
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
5